Report Scope:
The scope of this study encompasses the global and regional markets for Alzheimer's therapeutics and diagnostics. These markets are segmented by branded and generic drugs, mechanism of action, such as acetylcholine inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists, a combination drug of donepezil and memantine, tau aggregation inhibitors (TAI) and amyloid-beta (A?) vaccines. Drugs are also segmented by the stage of Alzheimer's disease they treat: mild to moderate, severe and prodromal.
BCC Research analyzed each market and its applications, regulatory environment, assistive technologies, market projections and market share. Issues discussed include the major drug profiles, clinical groundwork, technological features and trends. The regional markets for AD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Italy, Spain, Japan, China and India. These markets are grouped as North America, Europe and Asia-Pacific. The rest of the world markets are not addressed because of their economic insignificance with respect to this report.
Report Includes:
- An overview of the global market for Alzheimer's disease therapeutic and diagnostic technologies
- Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
- Review of programs in development and quantification of market opportunities
- Discussion of the market segments' economic environment, technological descriptions and issues, and applications
- Projections of usage in the major primary and secondary disease application areas
- Profiles of major players in the industry
REASONS FOR DOING THE STUDY
Alzheimer's disease cannot be prevented, cured or slowed, and it is a rapidly growing and serious health problem, affecting more than 17 million worldwide. Therapies for AD provide temporary and modest improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease progression. The immense size of the affected population and lack of appropriate and effective treatment offers a tremendous commercial opportunity.
The understanding of the underlying reasons and mechanisms involved in AD is very limited. Drug developers have been failing to demonstrate meaningful clinical benefits of treatment for a myriad of investigational compounds due to stringent regulations. High drug attrition rates and long drug approval times have driven pharmaceutical companies and technology ventures closer to each for collaboration. Specifically, diagnostic technology companies are rigorously trying to bring about effective biomarker technologies to assist and enhance the drug development process for prospective drug candidates. Regulatory bodies are highly supportive of the use of diagnostic technologies in order to improve drug attrition rates.
Despite the recurring failures in the development of novel therapies for AD, the global markets are demanding new and more effective, disease attenuating treatments, with first-in-class approvals. This expectation and the increasing incidence of AD associated with the aging population are driving the market.
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
Table of Contents
Chapter 1 Introduction
Study Objectives
Reasons For Doing the Study
Intended Audience
Scope of the Study
Information Sources
Methodology
Analyst's Credentials
Related Bcc Research Reports
Bcc Research Website
Disclaimer
Chapter 2 Summary
Chapter 3 Overview
Alzheimer's Disease: Definition and Market Structure
Alzheimer's Disease Pathophysiology
Ad and Amyloid Cascade
Ad and Tauopathy
Ad and Neurotransmitter Systems
Alzheimer's Disease Etiology
Genetic Factors
Non-Genetic Factors
Alzheimer's Disease Epidemiology
Age of Onset
Incidence, Prevalence and Mortality
Stages and Severity of Ad
Comorbidities
Diagnosis and Treatment of Alzheimer's
Diagnosis of Alzheimer's
Pharmaceutical Treatment of Ad
Chapter 4 Regulatory Landscape
U.S. Food and Drug Administration
European Medicines Agency
Chapter 5 Global Markets
Introduction
Market Dynamics
Top Players In the Global Market For Ad Therapeutics
Global Market For Ad Therapeutics and Diagnostics
Market By Region
Market By Application Segment
Chapter 6 North American Market For Alzheimer's Therapeutics and Diagnostics
North American Market
North American Market For Ad Therapeutics By Country
North American Market For Branded/Generic Ad Therapeutics
North American Market For Ad Therapeutics By Mechanism of Action
North American Market For Ad Therapeutics By Ad Stage
North American Market For Ad Diagnostics By Molecular Target
Chapter 7 European Markets For Alzheimer's Therapeutics and Diagnostics
European Markets
European Market For Ad Therapeutics By Country
European Market For Branded/Generic Ad Therapeutics
European Market For Ad Therapeutics By Mechanism of Action
European Market For Ad Therapeutics By Ad Stage
European Market For Ad Diagnostics
Chapter 8 Asia-Pacific Market For Alzheimer's Therapeutics and Diagnostics
Asia-Pacific Market
Asia-Pacific Market For Ad Therapeutics By Region
Asia-Pacific Market For Branded/Generic Ad Therapeutics
Asia-Pacific Market For Ad Therapeutics By Mechanism of Action
Asia-Pacific Market For Ad Therapeutics By Ad Stage
Asia-Pacific Market For Ad Diagnostics
Chapter 9 Pipeline Analysis
Ad Pipeline Landscape
Ad Pipeline: Clinical Stage
Ad Pipeline: Treatment Focus
Ad Pipeline By Disease Stage
Ad Pipeline: Mechanism of Action
Major Ab-Based Therapies In Clinical Trials
Biib037/Aducanumab
Solanezumab/Ly2062430
Rg1450/Gantenerumab
Rg7412/Crenezumab
Mk-8931/Verubecestat
Cad106
Major Tau-Based Therapies In Clinical Trials
Lmtx
Chapter 10 Companion Diagnostics
Introduction
Companion Imaging Diagnostics For Ad
Cidx Technologies For Amyloid Visualization
Cidx Technologies For Tau-Nft Visualization
Cidx Technologies: Ab Versus Tau Imaging Technologies
Concluding Remarks
Chapter 11 Company Profiles
Ab Science
Abbvie Inc.
Ac Immune Sa
Allergan Plc
Affiris Ag
Amarantus Bioscience Holdings
Anavex Life Sciences
Astrazeneca
Avid Radiopharmaceuticals
Axon Neuroscience
Axovant Sciences
Biogen
Boehringer Ingelheim
Daiichi Sankyo Co
Diagenic
Eisai
Eli Lilly
F. Hoffmann La Roche Ag
Ge Healthcare
H. Lundbeck A/S
Janssen Pharmaceuticals
Merck & Co
Navidea Biopharmaceuticals
Neurotrax Corp.
Novartis Pharma Services Ag
Ono Pharmaceutical Co.
Otsuka Pharmaceuticals
Pfizer Inc
Piramal Imaging Gmbh
Taurx Therapeutics
List of Tables
Summary Table : Global Market For Alzheimer's Therapeutics and Diagnostics By Region, Through 2020
Table 1 : Prevalence Rates of Alzheimer's By Region, 2014
Table 2 : Global Alzheimer's Population By Age Group and Region, 2014
Table 3 : Pharmacological Treatment of Bpsd of Alzheimer's
Table 4 : Computerized Screening Tests Used In Detecting Cognitive Impairment
Table 5 : Brain Imaging Technologies and Application In the Alzheimer's Context
Table 6 : Diagnostic Imaging Tracers Approved By the Fda
Table 7 : Global Market Shares of Leading Companies In Alzheimer's Therapeutics, 2020
Table 8 : Global Market For Alzheimer's Therapeutics and Diagnostics By Region, Through 2020
Table 9 : Global Market For Alzheimer's Therapeutics and Diagnostics By Application, Through 2020
Table 10 : Global Market For Alzheimer's Therapeutics By Region, Through 2020
Table 11 : Global Market For Generic/Branded Alzheimer's Therapeutics, Through 2020
Table 12 : Global Market For Alzheimer's Therapeutics By Mechanism of Action, Through 2020
Table 13 : Global Market For Branded/Generic Acetylcholinesterase Inhibitors, Through 2020
Table 14 : Global Market For Acetylcholinesterase Inhibitors By Region, Through 2020
Table 15 : Global Market For Branded/Generic Nmda Drugs, Through 2020
Table 16 : Global Market For Nmda Drugs By Region, Through 2020
Table 17 : Global Market For Other Alzheimer's Therapeutics By Region, Through 2020
Table 18 : Global Market For Alzheimer's Therapeutics By Disease Stage, Through 2020
Table 19 : Global Market For Alzheimer's Diagnostics By Region, Through 2020
Table 20 : Global Market For Alzheimer's Diagnostics By Molecular Target, Through 2020
Table 21 : North American Market For Alzheimer's Therapeutics and Diagnostics By Application Segment, Through 2020
Table 22 : North American Market For Alzheimer's Therapeutics By Country, Through 2020
Table 23 : North American Market For Branded/Generic Alzheimer's Therapeutics, Through 2020
Table 24 : North American Market For Alzheimer's Therapeutics By Mechanism of Action, Through 2020
Table 25 : North American Market For Branded/Generic Acetylcholinesterase Inhibitors, Through 2020
Table 26 : North American Market For Acetylcholinesterase Inhibitors By Country, Through 2020
Table 27 : North American Market For Branded/Generic Nmda Drugs, Through 2020
Table 28 : North American Market For Nmda Drugs By Country, Through 2020
Table 29 : North American Market For Other Alzheimer's Therapeutics By Country, Through 2020
Table 30 : North American Market For Alzheimer's Therapeutics By Disease Stage, Through 2020
Table 31 : North American Market For Alzheimer's Diagnostics By Molecular Target, Through 2020
Table 32 : European Market For Alzheimer's Therapeutics and Diagnostics By Application Segment, Through 2020
Table 33 : European Market For Alzheimer's Therapeutics By Country, Through 2020
Table 34 : European Market For Branded/Generic Alzheimer's Therapeutics, Through 2020
Table 35 : European Market For Alzheimer's Therapeutics By Mechanism of Action, Through 2020
Table 36 : European Market For Branded/Generic Acetylcholinesterase Inhibitors, Through 2020
Table 37 : European Market For Acetylcholinesterase Inhibitors By Country, Through 2020
Table 38 : European Market For Branded/Generic Nmda Drugs, Through 2020
Table 39 : European Market For Nmda Drugs By Country, Through 2020
Table 40 : European Market For Other Alzheimer's Therapeutics By Country, Through 2020
Table 41 : European Market For Alzheimer's Therapeutics By Disease Stage, Through 2020
Table 42 : European Market For Alzheimer's Diagnostics By Molecular Target, Through 2020
Table 43 : Asia-Pacific Market For Alzheimer's Therapeutics and Diagnostics By Application Segment, Through 2020
Table 44 : Asia-Pacific Market For Alzheimer's Therapeutics By Country, Through 2020
Table 45 : Asia-Pacific Market For Branded/Generic Alzheimer's Therapeutics, Through 2020
Table 46 : Asia-Pacific Market For Alzheimer's Therapeutics By Mechanism of Action, Through 2020
Table 47 : Asia-Pacific Market For Branded/Generic Acetylcholin-Esterase Inhibitors, Through 2020
Table 48 : Asia-Pacific Market For Acetylcholinesterase Inhibitors By Country, Through 2020
Table 49 : Asia-Pacific Market For Branded/Generic Nmda Drugs, Through 2020
Table 50 : Asia-Pacific Market For Nmda Drugs By Country, Through 2020
Table 51 : Asia-Pacific Market For Alzheimer's Therapeutics By Disease Stage, Through 2020
Table 52 : Asia-Pacific Market For Alzheimer's Diagnostics By Molecular Target, Through 2020
Table 53 : Global Alzheimer's Drugs In the Pipeline By Mechanism of Action
Table 54 : Cidx-Drug Pairs In Clinical Trials
List of Figures
Summary Figure : Global Market For Alzheimer's Therapeutics and Diagnostics By Region, 2014-2020
Figure 1 : Change In Alzheimer's Population and Cost of Care In the U.S., 2015-2030
Figure 2 : Global Prevalence Rates of Alzheimer's By Age Group and Region
Figure 3 : Global Alzheimer's Population By Age Group and Region, 2014
Figure 4 : Global Market Shares of Leading Companies In Alzheimer's Therapeutics, 2020
Figure 5 : Global Market Shares of Alzheimer's Therapeutics and Diagnostics By Region, 2015
Figure 6 : Global Market For Alzheimer's Therapeutics and Diagnostics By Region, 2014-2020
Figure 7 : Global Market For Alzheimer's Therapeutics and Diagnostics By Application, 2014-2020
Figure 8 : Global Market For Alzheimer's Therapeutics By Region, 2014-2020
Figure 9 : Global Market For Branded/Generic Alzheimer's Therapeutics, 2014-2020
Figure 10 : Global Market For Alzheimer's Therapeutics By Mechanism of Action, 2014-2020
Figure 11 : Global Market For Branded/Generic Acetylcholinesterase Inhibitors, 2014-2020
Figure 12 : Global Market For Acetylcholinesterase Inhibitors By Region, 2014-2020
Figure 13 : Global Market For Branded/Generic Nmda Drugs, 2014-2020
Figure 14 : Global Market For Nmda Drugs By Region, 2014-2020
Figure 15 : Global Market For Other Alzheimer's Therapeutics By Region, 2014-2020
Figure 16 : Global Market For Alzheimer's Therapeutics By Disease Stage, 2014-2020
Figure 17 : Global Market For Alzheimer's Diagnostics By Region, 2014-2020
Figure 18 : Global Market For Alzheimer's Diagnostics By Molecular Target, 2014-2020
Figure 19 : North American Market For Alzheimer's Therapeutics and Diagnostics By Application Segment, 2014-2020
Figure 20 : North American Market For Alzheimer's Therapeutics By Country, 2014-2020
Figure 21 : North American Market For Branded/Generic Alzheimer's Therapeutics, 2014-2020
Figure 22 : North American Market For Alzheimer's Therapeutics By Mechanism of Action, 2014-2020
Figure 23 : North American Market For Branded/Generic Acetylcholinesterase Inhibitors, 2014-2020
Figure 24 : North American Market For Acetylcholinesterase Inhibitors Market By Country, 2014-2020
Figure 25 : North American Market For Branded/Generic Nmda Drugs, 2014-2020
Figure 26 : North American Market For Nmda Drugs By Country, 2014-2020
Figure 27 : North American Market For Other Alzheimer's Therapeutics By Country, 2014-2020
Figure 28 : North American Market For Alzheimer's Therapeutics By Disease Stage 2014-2020
Figure 29 : North American Market For Alzheimer's Diagnostics By Molecular Target, 2014-2020
Figure 30 : European Market For Alzheimer's Therapeutics and Diagnostics By Application Segment, 2014-2020
Figure 31 : European Market For Alzheimer's Therapeutics By Country, 2014-2020
Figure 32 : European Market For Branded/Generic Alzheimer's Therapeutics, 2014-2020
Figure 33 : European Market For Alzheimer's Therapeutics By Mechanism of Action, 2014-2020
Figure 34 : European Market For Branded/Generic Acetylcholinesterase Inhibitors, 2014-2020
Figure 35 : European Market For Acetylcholinesterase Inhibitors By Country, 2014-2020
Figure 36 : European Market For Branded/Generic Nmda Drugs, 2014-2020
Figure 37 : European Market For Nmda Drugs By Country, 2014-2020
Figure 38 : European Market For Other Alzheimer's Therapeutics By Country, Through 2020
Figure 39 : European Market For Alzheimer's Therapeutics By Disease Stage, 2014-2020
Figure 40 : European Market For Alzheimer's Diagnostics By Molecular Target, 2014-2020
Figure 41 : Asia-Pacific Market For Alzheimer's Therapeutics and Diagnostics By Application Segment, 2014-2020
Figure 42 : Asia-Pacific Market For Alzheimer's Therapeutics By Country, Through 2020
Figure 43 : Asia-Pacific Market For Branded/Generic Alzheimer's Therapeutics, 2014-2020
Figure 44 : Asia-Pacific Market For Alzheimer's Therapeutics By Mechanism of Action, 2014-2020
Figure 45 : Asia-Pacific Market For Branded/Generic Acetylcholin-Esterase Inhibitors, 2014-2020
Figure 46 : Asia-Pacific Market For Acetylcholinesterase Inhibitors By Country, 2014-2020
Figure 47 : Asia-Pacific Market For Branded/Generic Nmda Drugs, 2014-2020
Figure 48 : Asia-Pacific Market For Nmda Drugs By Country, 2014-2020
Figure 49 : Asia-Pacific Market For Alzheimer's Therapeutics By Disease Stage, 2014-2020
Figure 50 : Asia-Pacific Market For Alzheimer's Diagnostics By Molecular Target, 2014-2020
Figure 51 : Alzheimer's Drugs In the Pipeline By Development Stage
Figure 52 : Alzheimer's Drugs In the Pipeline By Treatment Focus
Figure 53 : Late Phase Ii/Iii Alzheimer's Drugs By Disease Stage
Figure 54 : Global Clinical Trials On Alzheimer's Drug By Mechanism of Action
Figure 55 : Fda-Approved Cdx Technologies By Indicated Therapeutic Class
Figure 56 : Fda-Approved Cdx-Drug Pairs By Molecular Target
Figure 57 : Ongoing Ab and Tau Pet Imaging Clinical Trials
Figure 58 : Ab and Tau Pet Imaging Trials By Clinical Trial Phase
Global Antioxidant Vitamins Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 100
The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
Global Clavulanate Potassium Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 86
The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030.
North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
Global Amoxicillin Sodium Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 84
The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030.
North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
Global Melatonin Supplements Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 106
The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 93
The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
Global Sleeping Pills Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 94
The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
Global Zinc Oral Drops Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
Global Zinc Drops Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
Global Anti-Infectives Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 78
The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
